Shaping the Indications for Periodontal Adjunctive Antibiotics in Dental Practice: A PBRN Clinical Trial

确定牙科实践中牙周辅助抗生素的适应症:PBRN 临床试验

基本信息

项目摘要

Shaping the Indications for Periodontal Adjunctive Antibiotics in dental practice: A PBRN Clinical Trial Periodontitis is a bacterial inflammatory disease that has been reported to affect nearly 40% of Americans aged 30 years or older. If left untreated, periodontitis can lead to tooth loss and patient-perceived morbidity. Historically, antibiotic use has been an integral part of periodontal disease treatment. However, antibiotic stewardship calls for rationalizing their prescription to reduce antibiotic misuse and development of resistant strains. Across medical disciplines, there is a clear direction to identify individuals who in fact may benefit from antibiotic use and to provide guidelines for their use. As of 2018, the American Dental Association has developed evidence-based guidelines limiting circumstances for prophylactic antibiotic use in dental practice; however, no national guidelines exist for antibiotic use in treatment of periodontal infections because of lack of adequately powered trials assessing disease- and person-specific indications. Thus, dentists are left to decide when adjunctive antibiotics are indicated, and which dental patients need them to achieve periodontal health. In the context of periodontitis treatment, a biological rationale exists to support adjunctive antibiotic use against periodontal pathogenic bacteria, but clinical results of their use have presented conflicting results. Currently, very limited documentation of the prescription patterns and utilization of antibiotics as periodontal treatment adjuncts among US practitioners exist. Nonetheless, data from academic studies suggest that adjunctive systemic antibiotics may only be beneficial for certain populations, as the biological response to treatment is highly variable across individuals. This marked variability warrants the identification of person- and/or disease-related characteristics that are linked to maximum benefit from adjunctive antibiotic treatment. Consequently, clear guidelines can then be established for tailored indications for their use with the ultimate goal of minimizing antibiotic misuse in periodontal treatment to avoid development of antibiotic resistance. The objective of this study is to assess the effectiveness of adjunctive Amoxicillin/Metronidazole combination antibiotics to non-surgical periodontal therapy in clinical practices within the National Dental PBRN by conducting the largest randomized clinical trial (RCT) of adjunctive antibiotics. Further, within this PBRN study, current decision-making factors for adjunctive antibiotic prescription will be surveyed to assess the state of affairs in clinical practice. Importantly, leveraging the well-powered RCT dataset, high responders to adjunctive antibiotic treatment will be identified and the predictive validity of decision-making factors currently employed by clinicians will be assessed to develop clear indications for prescription. Collectively, results of adjunctive antibiotic use at present are ambiguous because indications are based on empirical information without evidence-based guidelines, which may lead to antibiotic misuse and lack of efficacy. The present pragmatic well-powered RCT was designed to enable the development of evidence-based guidelines for periodontal adjunctive antibiotic use.
塑造牙周辅助抗生素在牙科实践中的适应症:一项PBRN临床试验

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Georgios Kotsakis其他文献

Georgios Kotsakis的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Georgios Kotsakis', 18)}}的其他基金

Commensal modulation of Peri-implant Microbiome Dysbiosis via Veillonella parvula
小韦荣球菌对种植体周围微生物群失调的共生调节
  • 批准号:
    10899342
  • 财政年份:
    2023
  • 资助金额:
    $ 57.88万
  • 项目类别:
Shaping the Indications for Periodontal Adjunctive Antibiotics in Dental Practice: A PBRN Clinical Trial
确定牙科实践中牙周辅助抗生素的适应症:PBRN 临床试验
  • 批准号:
    10448940
  • 财政年份:
    2022
  • 资助金额:
    $ 57.88万
  • 项目类别:
Titanium particle-induced inflammasome activation in the peri-implant mucosal barrier
钛颗粒诱导种植体周围粘膜屏障炎症小体激活
  • 批准号:
    10360662
  • 财政年份:
    2021
  • 资助金额:
    $ 57.88万
  • 项目类别:
Titanium particle-induced inflammasome activation in the peri-implant mucosal barrier
钛颗粒诱导种植体周围粘膜屏障炎症小体激活
  • 批准号:
    10218850
  • 财政年份:
    2021
  • 资助金额:
    $ 57.88万
  • 项目类别:

相似海外基金

Establishment of optimal stimulation parameters and validation of indications for extracorporeal shock wave therapy for post-stroke spasticity.
建立最佳刺激参数并验证体外冲击波治疗中风后痉挛的适应症。
  • 批准号:
    23K10419
  • 财政年份:
    2023
  • 资助金额:
    $ 57.88万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
INDUCE: Development of siRNA-Mergo® therapeutics for lung indications.
INDUCE:开发针对肺部适应症的 siRNA-Mergo® 疗法。
  • 批准号:
    10072572
  • 财政年份:
    2023
  • 资助金额:
    $ 57.88万
  • 项目类别:
    Collaborative R&D
Shaping the Indications for Periodontal Adjunctive Antibiotics in Dental Practice: A PBRN Clinical Trial
确定牙科实践中牙周辅助抗生素的适应症:PBRN 临床试验
  • 批准号:
    10448940
  • 财政年份:
    2022
  • 资助金额:
    $ 57.88万
  • 项目类别:
Exploring the Attitudes, Barriers, Concerns, Differences, and Ethics (ABCDEs) of Healthcare Decision Making in Prospective Peripheral Indications for Vagus Nerve Stimulation Patients
探索迷走神经刺激患者预期外周适应症中医疗决策的态度、障碍、担忧、差异和道德 (ABCDE)
  • 批准号:
    10789644
  • 财政年份:
    2022
  • 资助金额:
    $ 57.88万
  • 项目类别:
Splicing Modulators for Rare Disease Indications
用于罕见疾病适应症的剪接调节剂
  • 批准号:
    10501840
  • 财政年份:
    2022
  • 资助金额:
    $ 57.88万
  • 项目类别:
A large prospective registry study to explore new indications for therapeutic hypothermia for neonatal encephalopathy
一项大型前瞻性登记研究,探索新生儿脑病低温治疗的新适应症
  • 批准号:
    22K07906
  • 财政年份:
    2022
  • 资助金额:
    $ 57.88万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Searching for biomarkers to discriminate the disease forms of adrenoleukodystrophy and to determine the indications for treatment
寻找生物标志物来区分肾上腺脑白质营养不良的疾病形式并确定治疗适应症
  • 批准号:
    22K07413
  • 财政年份:
    2022
  • 资助金额:
    $ 57.88万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Expanding the Indications for Xenotransplantation of Cultured Nasal Mucosa Epithelial Cells: Toward the Development of Application to Oral Mucosa Regeneration
扩大培养鼻粘膜上皮细胞异种移植的适应症:口腔粘膜再生应用的发展
  • 批准号:
    22K16906
  • 财政年份:
    2022
  • 资助金额:
    $ 57.88万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS
针对癌症和其他适应症开发的大分子药物的临床前毒理学
  • 批准号:
    10802090
  • 财政年份:
    2022
  • 资助金额:
    $ 57.88万
  • 项目类别:
PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS
针对癌症和其他适应症开发的大分子药物的临床前毒理学
  • 批准号:
    10605054
  • 财政年份:
    2022
  • 资助金额:
    $ 57.88万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了